Similar articles

• [Suboptimal results of Optimaal: treatment with ACE inhibitors remains the preferred therapy in patients with left ventricular dysfunction after acute myocardial infarct]].

  Danchin N. Danchin N. Herz. 2002 Dec;27(8):(18). Herz. 2002. PMID: 12608391 German. No abstract available.
• What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?

  Dickstein K. Dickstein K. Am Heart J. 2003 May;145(5):754-7. doi: 10.1016/S0002-8703(03)00168-6. Am Heart J. 2003. PMID: 12766730 No abstract available.
• [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2002 May 16;144(20):60-1. MMW Fortschr Med. 2002. PMID: 12119887 German. No abstract available.
• The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction.

  Bazunga M. Bazunga M. Conn Med. 1995 Nov;59(11):663-6. Conn Med. 1995. PMID: 8565511 Review. No abstract available.
• Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

  Devereux RB, Dahlöf B. Devereux RB, et al. Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435. Curr Med Res Opin. 2007. PMID: 17288698 Review.